Revolutionising Clinical Trials with Artificial Intelligence: A Paradigm Shift in Drug Development

AI is revolutionising clinical trials by improving efficiency, accuracy, and decision-making throughout the study process. Traditional clinical trials are frequently time-consuming, expensive, and constrained by factors such as patient recruiting delays, protocol complexity, data management concerns, and high dropout rates. To solve these limitations, AI technologies such as machine learning, natural language processing, predictive analytics, and deep learning are increasingly being integrated into clinical trials. AI-powered solutions offer quick patient identification and recruitment by analysing electronic health records, real-world data, and genomic databases. Predictive modelling enhances trial design by identifying the best outcomes, stratifying patient populations, and projecting potential dangers. During trial execution, AI improves real-time data monitoring, anomaly detection, and adverse event prediction, resulting in improved patient safety and regulatory compliance. Furthermore, decentralised and virtual trials benefit from AI-powered wearable devices and remote monitoring systems, which provide continuous data collection and increased participant involvement. It will be necessary to fully grasp the advantages of AI in clinical research. Despite its benefits, AI deployment in clinical trials poses problems such as data privacy concerns, algorithmic bias, regulatory uncertainties, and the necessity for uniform validation methods. Ethical issues and openness in AI models are essential for preserving confidence and achieving equitable healthcare results. Overall, AI has the potential to significantly accelerate medication development, cut costs, and improve clinical trial success rates. Continued collaboration between researchers, regulatory agencies, technology developers, and healthcare institutions will be required to fully exploit the benefits of AI in clinical research.